Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

3.3K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

DAla2-GIP-Glu-PAL exerts neuroprotective effect on diabetic retinopathy by attenuating microglia activation and regulating NF-κB/NLRP3 and Nrf2/HO-1 pathways.

Neuroscience letters·2026
Same author

Enabling gradient biomineralization and prestress with a macroscopic matrix: the fish swim bladder for bioprocessing-inspired fabrication.

Materials horizons·2026
Same author

OphFusionNet: Uncertainty-Driven Multi-Scale Multimodal Feature Fusion Network for Ophthalmic Diseases Classification.

IEEE transactions on medical imaging·2026
Same author

Sequential multimodal therapy for senile-onset Coats disease.

Photodiagnosis and photodynamic therapy·2026
Same author

Real-world effect of vitrectomy combined with intravitreal conbercept for treatment of vitreous haemorrhage in proliferative diabetic retinopathy (QILIN I): a prospective cohort study.

The British journal of ophthalmology·2026
Same author

A fully integrated microfluidic device for cell electrofusion and quick acquisition of hybridoma cells with high production of monoclonal antibody.

Biosensors & bioelectronics·2026

Related Experiment Video

Updated: May 12, 2025

Author Spotlight: Understanding Retinal Vessel Resilience and Disease Progression
04:36

Author Spotlight: Understanding Retinal Vessel Resilience and Disease Progression

Published on: January 12, 2024

992

Genetic Evidence Supporting a Causal Association Between mTORC1-Dependent Circulating Protein Levels and Diabetic

Yaqi Bai1, Yujia Xi2, Chenwei Gui3

  • 1The First Clinical Medical College, Shanxi Medical University, Taiyuan, Shanxi, China.

Translational Vision Science & Technology
|May 2, 2025
PubMed
Summary

Higher serum eIF4E levels promote diabetic retinopathy (DR) progression. This study suggests targeting eIF4E may offer a new therapeutic strategy for DR, a condition linked to mTOR signaling.

More Related Videos

Characterization of a Novel Human Organotypic Retinal Culture Technique
05:51

Characterization of a Novel Human Organotypic Retinal Culture Technique

Published on: June 9, 2021

3.8K
Quantification of Vascular Parameters in Whole Mount Retinas of Mice with Non-Proliferative and Proliferative Retinopathies
12:28

Quantification of Vascular Parameters in Whole Mount Retinas of Mice with Non-Proliferative and Proliferative Retinopathies

Published on: March 12, 2022

3.5K

Related Experiment Videos

Last Updated: May 12, 2025

Author Spotlight: Understanding Retinal Vessel Resilience and Disease Progression
04:36

Author Spotlight: Understanding Retinal Vessel Resilience and Disease Progression

Published on: January 12, 2024

992
Characterization of a Novel Human Organotypic Retinal Culture Technique
05:51

Characterization of a Novel Human Organotypic Retinal Culture Technique

Published on: June 9, 2021

3.8K
Quantification of Vascular Parameters in Whole Mount Retinas of Mice with Non-Proliferative and Proliferative Retinopathies
12:28

Quantification of Vascular Parameters in Whole Mount Retinas of Mice with Non-Proliferative and Proliferative Retinopathies

Published on: March 12, 2022

3.5K

Area of Science:

  • Ophthalmology
  • Genetics
  • Molecular Biology

Background:

  • The mechanistic target of rapamycin (mTOR) pathway is crucial in diabetic retinopathy (DR) development.
  • The specific roles of mTORC1 downstream proteins in DR pathogenesis are not fully understood.

Purpose of the Study:

  • To investigate the causal relationship between mTORC1 downstream proteins and the risk of diabetic retinopathy (DR).
  • To assess the potential of targeting these proteins for DR treatment.

Main Methods:

  • Employed Mendelian randomization (MR) using summary statistics from the INTERVAL and FinnGen studies.
  • Utilized inverse-variance-weighted, weighted median, and MR-Egger methods.
  • Conducted sensitivity analyses to detect pleiotropy and heterogeneity.

Main Results:

  • Elevated genetically predicted eukaryotic initiation factor 4E (eIF4E) showed a positive correlation with DR risk (OR = 1.057, P = 0.022).
  • No significant associations were found for RP-S6K, eIF4G, eIF4A, eIF4E-BP, or eIF4B with DR.
  • Sensitivity analyses indicated no significant heterogeneity or pleiotropy.

Conclusions:

  • Increased serum eIF4E levels are implicated in promoting diabetic retinopathy progression.
  • Pharmacological inhibition of eIF4E presents a potential therapeutic avenue for DR treatment.
  • This research establishes eIF4E as a key factor in DR development, guiding future research into novel therapeutic targets.